- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02153229
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (MPM-PDT)
August 31, 2023 updated by: Abramson Cancer Center at Penn Medicine
A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma
A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves
OS in the treatment of patients with epithelioid MPM.
Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery .
All subjects will receive maximal surgical debulking.
Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
102
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sally McNulty, RN
- Phone Number: 215-662-7720
- Email: Sally.McNulty@uphs.upenn.edu
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Rosewell Park
-
Principal Investigator:
- Sai Yendamuri, MD
-
Contact:
- Kelly Dunn, MPH, CCRP
- Phone Number: 6537 716-845-1300
- Email: kelly.dunn@roswellpark.org
-
Contact:
- Elongia Farrell, BA, CCRC
- Phone Number: 716-845-3114
- Email: elongia.farrell@roswellpark.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Abramson Cancer Center of the University of Pennsylvania
-
Contact:
- Sally McNulty, RN
- Phone Number: 215-662-7720
- Email: Sally.McNulty@uphs.upenn.edu
-
Contact:
- Keith Cengel, MD, PhD
- Phone Number: 855-216-0098
- Email: PennCancerTrials@emergingmed.com
-
Principal Investigator:
- Keith Cengel, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with a histologic diagnosis of MPM, epithelioid subtype, who in the opinion of the attending thoracic surgeon can receive a macroscopically complete resection of tumor.
- Patients must have disease limited to the hemithorax.
- Patients who have received prior surgery, gene therapy, or combination chemotherapy will be permitted if it has been at least 30 days since the last treatment.
- Subjects treated with pemetrexed previously will be eligible only if 30 days have elapsed between the last dose of pemetrexed and the date of surgery.
- ECOG performance status of 0-1.
- Medical suitability for resection, including documented medical and cardiac clearance.
- 18 years of age or older.
- Patients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks. Patients unwilling or unable due to cognitive impairment to sign informed consent are excluded from the study.
EXCLUSION CRITERIA
- Patients with active invasive cancers, other than MPM, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer
- Pregnant or lactating patients.
- Patients who have a history of HIV disease.
- Patients who have a white count less than 2,500 per cubic mm or platelets less than 100,000/cubic mm.
- Serum creatinine equal or greater than 2.5 mg/deciliter.
- Patients who have severe liver disease including cirrhosis, Grade III-IV elevations in liver function studies, or bilirubin in excess of 1.5 mg/deciliter.
- Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.
- Patients who have been treated with pemetrexed if the last dose of pemetrexed is < 30 days to the date of surgery.
- Patients that have been treated with prior Mantle field radiation.
- Patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax.
- Subjects who have received more than 2 doses of neo-adjuvant chemotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: patients who undergo RP plus photofrin-based PDT
|
Other Names:
Other Names:
If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
|
Experimental: patients who undergo RP alone
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Survival months
Time Frame: 4 years
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival months
Time Frame: 4 years
|
4 years
|
|
Local Control
Time Frame: 4 years
|
progression with death as a competing risk
|
4 years
|
Receipt of Pembrolizumab
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Keith Cengel, MD, PhD, Abramson Cancer Center at Penn Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
May 28, 2014
First Submitted That Met QC Criteria
June 2, 2014
First Posted (Estimated)
June 3, 2014
Study Record Updates
Last Update Posted (Actual)
September 1, 2023
Last Update Submitted That Met QC Criteria
August 31, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Adenoma
- Neoplasms, Mesothelial
- Pleural Neoplasms
- Mesothelioma
- Mesothelioma, Malignant
- Antineoplastic Agents
- Photosensitizing Agents
- Dermatologic Agents
- Dihematoporphyrin Ether
Other Study ID Numbers
- UPCC 14513
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epitheliod Malignant Pleural Mesothelioma
-
NRG OncologyNational Cancer Institute (NCI)TerminatedPleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...United States, Canada
-
National Cancer Institute (NCI)Active, not recruitingBiphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...United States
-
University of ChicagoNational Cancer Institute (NCI)Active, not recruitingBiphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditionsUnited States
-
RS Oncology LLCRecruitingMesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; LungUnited Kingdom
-
Health Pharma Professional ResearchWithdrawnMalignant Pleural Mesothelioma, Advanced | Malignant Pleural Mesothelioma, UnresectableMexico
-
National Cancer Institute (NCI)TerminatedEpithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural MesotheliomaUnited States
-
National Cancer Institute (NCI)WithdrawnMalignant Pleural Mesotheliomas (Mpm) | Malignant Pleural Effusions (Mpe) | Epithelial Tumors, Malignant | Pleural Effusions, Malignant | Mesothelin (Msln)United States
-
Royal Marsden NHS Foundation TrustMerck Sharp & Dohme LLCTerminatedAdvanced Malignant Pleural MesotheliomaUnited Kingdom
-
Swiss Group for Clinical Cancer ResearchCompletedMalignant Pleural Mesothelioma, AdvancedSwitzerland, Italy
-
Istituto Clinico HumanitasCompletedMALIGNANT PLEURAL MESOTHELIOMAItaly
Clinical Trials on Photodynamic Therapy
-
Centre Hospitalier Universitaire de NiceWithdrawnDystrophic Epidermolysis BullosaFrance
-
National Taiwan University HospitalCompleted
-
photonamic GmbH & Co. KGCompletedActinic KeratosisGermany
-
University of KansasDUSA Pharmaceuticals, Inc.CompletedHidradenitis SuppurativaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Non-small Cell Lung Cancer | Stage 0 Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung CancerUnited States
-
Northwestern UniversityCompleted
-
Bispebjerg HospitalCompletedActinic KeratosesDenmark
-
Bispebjerg HospitalCompleted
-
Fujian Longhua Pharmaceutical Co. LtdSun Yat-sen University; Fuzhou UniversityUnknownEsophageal Cancer | Skin CancerChina
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedAggressive PeriodontitisBrazil